DK3223796T3 - Farmaceutiske sammensætninger, fremstilling og anvendelser deraf - Google Patents

Farmaceutiske sammensætninger, fremstilling og anvendelser deraf Download PDF

Info

Publication number
DK3223796T3
DK3223796T3 DK15800774.0T DK15800774T DK3223796T3 DK 3223796 T3 DK3223796 T3 DK 3223796T3 DK 15800774 T DK15800774 T DK 15800774T DK 3223796 T3 DK3223796 T3 DK 3223796T3
Authority
DK
Denmark
Prior art keywords
manufacturing
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
DK15800774.0T
Other languages
English (en)
Inventor
Agnès Pottier
Laurence Poul
Marion Paolini
Marie-Edith Meyre
Matthieu Germain
Original Assignee
Curadigm Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curadigm Sas filed Critical Curadigm Sas
Application granted granted Critical
Publication of DK3223796T3 publication Critical patent/DK3223796T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK15800774.0T 2014-11-25 2015-11-24 Farmaceutiske sammensætninger, fremstilling og anvendelser deraf DK3223796T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14306876 2014-11-25
PCT/EP2015/077441 WO2016083338A1 (en) 2014-11-25 2015-11-24 Pharmaceutical compositions, preparation and uses thereof

Publications (1)

Publication Number Publication Date
DK3223796T3 true DK3223796T3 (da) 2021-09-27

Family

ID=52013983

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15800774.0T DK3223796T3 (da) 2014-11-25 2015-11-24 Farmaceutiske sammensætninger, fremstilling og anvendelser deraf

Country Status (12)

Country Link
US (1) US11304902B2 (da)
EP (1) EP3223796B1 (da)
JP (1) JP6835733B2 (da)
AR (1) AR102780A1 (da)
DK (1) DK3223796T3 (da)
ES (1) ES2890662T3 (da)
HU (1) HUE056175T2 (da)
LT (1) LT3223796T (da)
PL (1) PL3223796T3 (da)
PT (1) PT3223796T (da)
TW (1) TW201628610A (da)
WO (1) WO2016083338A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10413509B2 (en) * 2013-05-30 2019-09-17 Nanobiotix Pharmaceutical composition, preparation and uses thereof
WO2016083331A1 (en) 2014-11-25 2016-06-02 Nanobiotix Pharmaceutical composition, preparation and uses thereof
SG11201704219UA (en) 2014-11-25 2017-06-29 Nanobiotix Pharmaceutical composition, preparation and uses thereof
FI3229776T3 (fi) 2014-11-25 2023-08-15 Curadigm Sas Farmaseuttinen koostumus, joka yhdistää ainakin kaksi erillistä nanopartikkelia ja farmaseuttisen yhdisteen, sen valmistus ja käytöt
BR112017025553A2 (pt) 2015-05-28 2018-08-07 Nanobiotix composição de vacina, e kit
US20220143011A1 (en) 2017-05-16 2022-05-12 Bow River LLC Methods of treatment with cyp3a4 substrate drugs
US10857144B2 (en) 2017-05-16 2020-12-08 Bow River LLC Methods of treatment
JP2020520380A (ja) * 2017-05-16 2020-07-09 ボウ リバー エルエルシー 処置法
US10835529B2 (en) 2017-05-16 2020-11-17 Bow River LLC Methods of treatment with CYP3A4 substrate drugs

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4280918A (en) 1980-03-10 1981-07-28 International Business Machines Corporation Magnetic particle dispersions
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
GB9509321D0 (en) * 1995-05-09 1995-06-28 Zylepsis Ltd Methods of and substances for inhibiting oxidative enzymes
AU4821697A (en) * 1996-10-18 1998-05-15 Wayne State University 6',7'-dihydroxybergamottin, a cytochrome p450 ihnibitor in grapefruit juice
JPH10120597A (ja) 1996-10-22 1998-05-12 Eiken Chem Co Ltd リンパ節高集積性コロイド粒子
PT1007034E (pt) * 1997-08-19 2004-03-31 Warner Lambert Co Combinacoes que contem bergamotina para aumentar a biodisponibilidade oral de agentes farmaceuticos
GB0002835D0 (en) 2000-02-09 2000-03-29 Melvin William T Drug resistance in cancer
US8178123B2 (en) * 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
US20050090732A1 (en) 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
CA2547024C (en) 2003-12-22 2013-12-17 Bracco Research Sa Gas-filled microvesicle assembly for contrast imaging
EP1720521A4 (en) * 2004-02-10 2008-11-05 Barnes Jewish Hospital IMPROVED EFFICIENCY AND SAFETY OF TARGETED MEANS WITH DECOY SYSTEMS
US20060264804A1 (en) 2005-04-07 2006-11-23 Yoram Karmon Device and kit for delivery of encapsulated substances and methods of use thereof
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
EP2000150B1 (en) 2006-03-24 2016-07-13 Toto Ltd. Titanium oxide complex particle, dispersion solution of the particle, and process for production of the particle
WO2007116954A2 (en) 2006-03-30 2007-10-18 Fujifilm Corporation Inorganic nanoparticle comprising an active substance immobilized on the surface and a polymer
WO2007128066A1 (en) 2006-05-04 2007-11-15 University Of South Australia Drug release from nanoparticle-coated capsules
WO2009026427A2 (en) 2007-08-21 2009-02-26 Alza Corporation Liposome compositions for in vivo administration of boronic acid compounds
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
US20100272639A1 (en) 2007-12-21 2010-10-28 John Robert Dutcher Polysaccharide nanoparticles
WO2009105774A2 (en) * 2008-02-21 2009-08-27 Sequoia Pharmaceuticals, Inc. Amino acid inhibitors of cytochrome p450
WO2009142754A1 (en) 2008-05-22 2009-11-26 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dendritic conjugates and methods of use
EP2130553A1 (en) 2008-06-05 2009-12-09 Nanobiotix Inorganic nanoparticles of high density to destroy cells in-vivo
US20130023714A1 (en) 2008-10-26 2013-01-24 Board Of Regents, The University Of Texas Systems Medical and Imaging Nanoclusters
GB0921596D0 (en) 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
US8470891B2 (en) * 2009-12-23 2013-06-25 International Business Machines Corporation Biodegradable block polymers for drug delivery, and methods related thereto
EP2537530A4 (en) 2010-02-17 2015-12-16 Nat Univ Corp Univ Kobe RADIOTHERAPY AGENT
CA3051495A1 (en) 2010-03-26 2011-09-29 Abraxis Bioscience, Llc Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma
GB201009455D0 (en) 2010-06-04 2010-07-21 King S College London Nanoparticles and their uses in molecular imaging
WO2012051220A1 (en) 2010-10-11 2012-04-19 Wichita State University Composite magnetic nanoparticle drug delivery system
RU2013117288A (ru) * 2010-12-17 2015-01-27 Эрроухэд Рисерч Корпорейшн СОДЕРЖАЩАЯ ГАЛАКТОЗНЫЙ КЛАСТЕР НАЦЕЛИВАЮЩАЯ ГРУППА ДЛЯ миРНК, МОДУЛИРУЮЩАЯ ФОРМАКОКИНЕТИЧЕСКИЕ СВОЙСТВА
WO2012104277A2 (en) 2011-01-31 2012-08-09 Nanobiotix Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles.
EA024930B1 (ru) 2011-01-31 2016-11-30 Нанобиотикс Системы доставки наночастиц, их получение и применение
US10251841B2 (en) 2011-10-17 2019-04-09 Trustees Of Boston University Polymeric depots for localization of agent to biological sites
CN102532154B (zh) * 2012-01-11 2014-05-14 昆明医学院 隆萼当归线型呋喃香豆素化合物及其应用
WO2014039874A2 (en) 2012-09-07 2014-03-13 Carnegie Mellon University Methods and materials for reducing reticuloendothelial system clearance of particles from a subject
ITRM20120480A1 (it) 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
KR101378430B1 (ko) * 2012-11-05 2014-03-27 초당약품공업 주식회사 세스퀴터핀 락톤계 위장 질환 치료용 의약 조성물
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
US10413509B2 (en) 2013-05-30 2019-09-17 Nanobiotix Pharmaceutical composition, preparation and uses thereof
EP2886128A1 (en) 2013-12-20 2015-06-24 Nanobiotix Pharmaceutical composition comprising nanoparticles, preparation and uses thereof
FI3229776T3 (fi) 2014-11-25 2023-08-15 Curadigm Sas Farmaseuttinen koostumus, joka yhdistää ainakin kaksi erillistä nanopartikkelia ja farmaseuttisen yhdisteen, sen valmistus ja käytöt
US20170258718A1 (en) 2014-11-25 2017-09-14 Nanobiotix Pharmaceutical composition, preparation and uses thereof
SG11201704219UA (en) 2014-11-25 2017-06-29 Nanobiotix Pharmaceutical composition, preparation and uses thereof
WO2016083331A1 (en) 2014-11-25 2016-06-02 Nanobiotix Pharmaceutical composition, preparation and uses thereof

Also Published As

Publication number Publication date
US11304902B2 (en) 2022-04-19
EP3223796A1 (en) 2017-10-04
EP3223796B1 (en) 2021-07-21
AR102780A1 (es) 2017-03-22
WO2016083338A1 (en) 2016-06-02
PT3223796T (pt) 2021-09-28
LT3223796T (lt) 2021-10-25
TW201628610A (zh) 2016-08-16
JP6835733B2 (ja) 2021-02-24
ES2890662T3 (es) 2022-01-21
US20170258720A1 (en) 2017-09-14
PL3223796T3 (pl) 2021-12-20
JP2017536419A (ja) 2017-12-07
HUE056175T2 (hu) 2022-01-28

Similar Documents

Publication Publication Date Title
DK3529248T3 (da) Farmaceutiske sammensætninger
BR112016023628A2 (pt) composições farmacêuticas.
DK3495023T3 (da) Semifluorerede forbindelser og sammensætninger deraf
DK3297605T3 (da) Topiske, farmaceutiske sammesætninger
DK3230281T3 (da) 1,3-thiazol-2-yl-substituerede benzamider
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
DK3154594T3 (da) Fap-aktiverede, terapeutiske midler og anvendelser i forbindelser dermed
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3015526T3 (da) Hydrofluorolefinbaseret sammensætning og anvendelse deraf
DK3160978T3 (da) Gemcitabin-prodrugs
DK3223796T3 (da) Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
DK3137168T3 (da) Substituerede 4-phenylpiperidiner, deres fremstilling og anvendelse
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
DK3199161T3 (da) Farmaceutisk præparat
DK3209773T3 (da) Prolintolerante tripeptidylpeptidaser og anvendelser deraf
DK3239269T3 (da) Sammensætning, der omfatter hfc og hfo
DK3283058T3 (da) Ribociclib-tablet
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
DK3463345T3 (da) Farmaceutiske kombinationer
DK3383397T3 (da) Farmaceutiske sammensætninger indeholdende doravirin, tenofovirdisoproxilfumarat og lamivudin
DK3388085T3 (da) Farmaceutisk sammensætning og anvendelser deraf
DK3229843T3 (da) Farmaceutisk sammensætning, præparat og anvendelser deraf
DK3157506T3 (da) Smagsmaskeret oral, farmaceutisk sammensætning
DK3365321T3 (da) Solabegron-zwitterion og anvendelser deraf